Bavarian Nordic A/S Bavarian Nordic A/S

Bavarian Nordic A/S

BAVA

Rang in aandelen #4989
Hellerup, Denmark-based Bavarian Nordic A/S, founded in 1992, specializes in... Hellerup, Denmark-based Bavarian Nordic A/S, founded in 1992, specializes in the research, production, and global distribution of vital, life-saving vaccines. The company's commercialized offerings include non-replicating vaccines for smallpox and monkeypox, marketed as IMVAMUNE, IMVANEX, and JYNNEOS. Additionally, their portfolio features Rabipur/RabAvert for rabies prevention, Encepur for tick-borne encephalitis, and MVABEA, an Ebola vaccine. Bavarian Nordic also maintains a robust pipeline of investigational treatments. This includes MVA-BN (freeze-dried), which has successfully completed Phase III clinical trials for smallpox; MVA-BN RSV, currently in Phase III development for respiratory syncytial virus; ABNCoV2, which completed Phase II trials targeting SARS-CoV-2; and TAEK-VAC, presently in Phase I/II trials for advanced HER2 and brachyury-expressing cancers. The firm engages in key partnerships, notably a license and collaboration agreement with AdaptVac, and licensing agreements with both the National Cancer Institute and the Public Health Service. Bavarian Nordic operates across a wide international footprint, with a presence in countries such as the United States, Germany, Belgium, France, Canada, the United Kingdom, Hong Kong, Saudi Arabia, Australia, Switzerland, and numerous other global markets.
Aandeelprijs
$38.42
Laatst gesynchroniseerd: 2026-10-20
Marktkapitalisatie
$2.92B
Verandering (1 dag)
1.77%
Verandering (1 jaar)
3.23%
Land
DK
Handel Bavarian Nordic A/S (BAVA)

Categorie

Healthcare
P/S-ratio voor Bavarian Nordic A/S (BAVA)
P/S-ratio op 2026 TTM: 0
Volgens de meest recente financiële rapporten en aandelenkoers van Bavarian Nordic A/S is de huidige P/S-ratio (TTM) 0. Eind 2026 had het bedrijf een P/S-ratio van 0.
P/S-ratiohistoriek voor Bavarian Nordic A/S van 2026 tot 2026
P/S-ratio aan het einde van elk jaar
Jaar P/S-ratio Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
P/S-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/S-ratio Verschil in P/S-ratio Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.02 -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
40.55 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.96 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.15 -
NL